Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing
CNS Experts Hired As Contera Built Out
Executive Summary
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.